Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press116810.17650/1726-9776-2006-2-3-40-44DIAGNOSIS AND TREATMENT OF URINARY TRACT TUMORS. CANCER OF THE URETHRA AND PENISДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. РАК УРЕТРЫ И ПОЛОВОГО ЧЛЕНАResults of combined and radiation therapy for cancer of the urethraРезультаты комбинированного и лучевого лечения рака уретрыMatveyevV. B.МатвеевВ. Б.
Russian Federation
GridnevaYa. V.ГридневаЯ. В.
Russian Federation
N.N. Blokhin Oncological Research Center, Russian Academy of Medical SciencesГУ РОНЦ им. Н.Н. Блохина РАМН300920062340441802202018022020https://oncourology.abvpress.ru/oncur/article/view/1168

Clinical course of primary urethral cancer is characterized in detail in 31 patients. Specific features in the disease course with consideration for tumor stage and patient's sex are analyzed. Urethral cancer is diagnosed only at stages III—IV in the majority (74.2%) of cases. The disease is more incident in women aged over 60 years with a history of chronic cystitis, urethritis, and urethral leukoplakia. The main clinical manifestations of primary urethral cancer are bloody discharge from the urethra, painful difficult urination, and palpated tumor. The symptoms persist for 12.06 months on average. The treatment efficiency depends on the stage of the process: complete effect is attained in 100% patients with stage I, in 75% with stage II, in 54.55% with stage III, and in 41.67% with stage IV. Local relapses are significantly more incident in men (50% vs. only 5.26% in women), 5-year uneventful survival is significantly better in women: 59.6%, vs. 31.2% in men. The median total survival of patients with primary urethral cancer is 61.3 months, total 5-year survival 53±11.6%. Evaluation of the results of different treatments for primary urethral cancer demonstrated the advantages of surgical and combined treatment vs. radiotherapy as a monotreatment. Radiotherapy should be carried out only when surgical removal of the tumor is impossible.

.

1. Gheiler E.L., Tefilli M.V., Tiguert R. et al. Management of primary urethral cancer. Urology 1998;52(3): 487–93.Gheiler E.L., Tefilli M.V., Tiguert R. et al. Management of primary urethral cancer. Urology 1998;52(3): 487–93.2. Anderson K., McAninch J. Primary squamous cell carcinoma of anterior male urethral. Urology 1984, 23: 134–40.Anderson K., McAninch J. Primary squamous cell carcinoma of anterior male urethral. Urology 1984, 23: 134–40.3. Klein F.A., Whitmore W.F., Herr H.W. et al. Inferior pubic rami resection with en bloc radical excision of invasive proximal urethral carcinoma. Cancer 1983; 51:1238–42.Klein F.A., Whitmore W.F., Herr H.W. et al. Inferior pubic rami resection with en bloc radical excision of invasive proximal urethral carcinoma. Cancer 1983; 51:1238–42.4. Dalbagni G., Zhang Z.F., Lacombe L., Herr H.W. Female urethral carcinoma: analysis of treatment outcome and plea for a standardized management strategy. BJU Int 1998; 82(6): 835–8.Dalbagni G., Zhang Z.F., Lacombe L., Herr H.W. Female urethral carcinoma: analysis of treatment outcome and plea for a standardized management strategy. BJU Int 1998; 82(6): 835–8.5. Dalbagni G., Zhang Z.F., Lacombe L. Herr H.W. Male urethral carcinoma: analysis of treatment outcome. Urology 1999; 53(6): 1126–32.Dalbagni G., Zhang Z.F., Lacombe L. Herr H.W. Male urethral carcinoma: analysis of treatment outcome. Urology 1999; 53(6): 1126–32.6. Goodman M., Tarnoff M., Kain M., Slotman G. and the Southern New Jersey Head and Neck Cancer Treatmen Group. Interactions between outcomes and and response to preoperative cispletin-sensitized radiotherapy in advanced head and neck cancer. Am J Surg 1997;174:527–31.Goodman M., Tarnoff M., Kain M., Slotman G. and the Southern New Jersey Head and Neck Cancer Treatmen Group. Interactions between outcomes and and response to preoperative cispletin-sensitized radiotherapy in advanced head and neck cancer. Am J Surg 1997;174:527–31.